Anthracycline-based chemotherapy can result in the development of a cumulative and
progressively developing cardiomyopathy. Doxorubicin is one of the most highly prescribed …

Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …

Doxorubicin (Adriamycin®) is a potent and broad‐spectrum antineoplastic agent prescribed
for the treatment of a variety of cancers, including both solid tumours and leukaemias …

Doxorubicin (DOX) is a chemotherapeutic drug that is utilized for solid tumors and
hematologic malignancies, but its clinical application is hampered by life-threatening …

Anthracyclines is an effective chemotherapeutic treatment used for many types of cancer.
However, high cumulative dosage of anthracyclines leads to cardiac toxicity and heart …

Anthracyclines remain the cornerstone of treatment in many malignancies but these agents
have a cumulative dose relationship with cardiotoxicity. Development of cardiomyopathy …

Anthracyclines, such as doxorubicin, are effective chemotherapeutic agents for the treatment
of cancer, but their clinical use is associated with severe and potentially life-threatening …

Cardiac side effects are a major drawback of anticancer therapies, often requiring the use of
low and less effective doses or even discontinuation of the drug. Among all the drugs known …

Anthracyclines, such as doxorubicin, represent one group of chemotherapy drugs with the
most cardiotoxicity. Despite that anthracyclines are capable of treating assorted solid tumors …

Doxorubicin (Dox) is a highly effective anticancer drug but cause acute ventricular
dysfunction, and also induce late-onset cardiomyopathy and heart failure. Despite extensive …